Guideline narrative review discusses diabetes risks from immunosuppressive therapy in kidney transplant recipients.
Guidelines address diabetes risks in kidney transplant patients
This publication is a narrative review guideline addressing Post-transplant diabetes mellitus and Type 2 Diabetes. The scope covers kidney t…
New guidance outlines considerations for kidney transplant patients dealing with diabetes and medication risks associated with therapy.
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
CFZ533 vs Tacrolimus in Kidney Transplant: Phase 2 Study Terminated After Interim Analysis
Did a new drug for kidney transplant patients work better than standard treatment?
A Phase 2 study comparing the anti-CD40 monoclonal antibody CFZ533 to tacrolimus for preventing organ rejection in kidney transplant recipie…
A planned five-year kidney transplant drug trial ended early after an interim look, leaving the key question about the new treatment's perfo…